The original success of the copyright undeniably revolutionized the medication landscape, but investing in companies strongly reliant on generic versions presents a complex picture. While early returns were substantial, the expiration of patents and the rise of less expensive alternatives have eroded sales. Consequently, a thorough analysis of pres